Henan Dingxin Pharmaceutical Technology Co., Ltd. was established in August 2022 with a registered capital of 125 million yuan. It is located at 2369 Muye Avenue (South), High tech Zone, Xinxiang City, Henan Province. It is a member enterprise controlled by Xinxiang Tuoxin Pharmaceutical Co., Ltd. (stock code 301089), a listed company on the Shenzhen Growth Enterprise Market. Its predecessor was Xinxiang Tuoxin Pharmaceutical Co., Ltd. Jingquan Branch, which integrates chemical synthesis A high-tech enterprise that integrates the production and sales of pharmaceutical intermediates and active pharmaceutical ingredients in the fermentation nucleoside series. It is one of the strong research and production bases for nucleoside and nucleotide drugs in China. The company covers an area of over 140 acres with a construction area of 34000 square meters, and currently has more than 600 employees.

The company's main products include cytosine, 5F cytosine, cytidine, uracil, uridine, adenosine, etc. The company passed the "three standard integrated" system certification in December 2022, and its products are exported to more than 20 countries and regions such as the United States, Italy, Spain, Japan, India, and South Korea. The export of products is increasing day by day, and it has strong international competitiveness and market development capabilities.